Trial Profile
A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evocalcet (Primary) ; Cinacalcet
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Aug 2014 New trial record